Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline ProgressBusiness Wire • 03/06/25
Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025Business Wire • 03/05/25
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025Business Wire • 02/24/25
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccinePRNewsWire • 02/14/25
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateBusiness Wire • 02/04/25
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19Business Wire • 01/31/25
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech ConferenceBusiness Wire • 01/30/25
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 01/06/25
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/16/24
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialBusiness Wire • 11/11/24
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/24
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline ProgressBusiness Wire • 11/07/24
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024Business Wire • 10/31/24
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/30/24
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's ComirnatyZacks Investment Research • 10/01/24
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationBusiness Wire • 09/30/24
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaPRNewsWire • 09/13/24